Welcome to our dedicated page for Biomerica SEC filings (Ticker: BMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Biomerica’s journey from innovative inFoods® IBS diagnostics to full commercial rollout means following every SEC disclosure—not just skimming headlines. Investors often search for R&D spending, FDA correspondence and patent updates buried deep inside the Biomerica annual report 10-K simplified or the Biomerica quarterly earnings report 10-Q filing. This page brings those details forward.
Stock Titan’s platform collects every form—10-K, 10-Q, 8-K, DEF 14A, S-1—and adds AI-powered summaries so understanding Biomerica SEC documents with AI feels intuitive. Need Biomerica insider trading Form 4 transactions before a material trial announcement? Our real-time feed flags each Biomerica Form 4 insider transactions real-time and breaks down who bought, who sold, and at what price. Curious how the board rewards leadership? The Biomerica proxy statement executive compensation section is annotated for quick ratio analysis.
Whether you’re comparing segment revenue from gastrointestinal tests quarter-over-quarter or scanning an Biomerica 8-K material events explained alert on new clinical data, the interface keeps research efficient. Practical use cases include:
- Monitoring Biomerica earnings report filing analysis to model cash runway
- Cross-checking patent disclosures against competitive pipelines
- Setting alerts for Biomerica executive stock transactions Form 4 to gauge management sentiment
Biomerica, Inc. (BMRA) filed its definitive proxy for the 2025 Annual Meeting set for December 12, 2025 at 10:00 a.m. PT, to be held virtually and at the company’s Irvine office. Stockholders will vote to elect five directors, approve a non-binding say-on-pay, ratify Haskell & White LLP as auditor, amend the 2024 Stock Incentive Plan to add 200,000 shares (bringing the plan total to 400,000 shares), authorize the Board to increase authorized common shares from 25,000,000 to 300,000,000, and approve a potential adjournment.
As of the record date October 15, 2025, shares outstanding were 2,947,966. The proxy outlines voting standards, broker discretion on routine items, and committee leadership, with the Audit Committee chaired by Eric Bing Chin. The compensation discussion highlights an equity‑heavy approach and recent restricted stock grants to executives. Auditor fees totaled $192,687 for fiscal 2025. The Board recommends voting “FOR” all proposals, including the share authorization and equity plan increase.
Biomerica (BMRA) reported Q1 FY2026 results showing lower sales but a break-even bottom line aided by a one-time credit. Net sales were $1.38 million, down from $1.81 million a year ago, as retail activity softened, international OTC demand eased, and contract manufacturing declined. Mix improvements and prior cost reductions lifted gross profit to $424,000 from $289,000, reducing the operating loss to $1.12 million from $1.37 million.
Other income surged to $1.12 million, primarily from a $1.10 million Employee Retention Credit, resulting in net income of $2,000 versus a $1.32 million loss last year. Cash rose to $3.05 million and working capital to $4.21 million, helped by an ATM sale of 258,569 shares for $939,000 gross and $912,000 net.
Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing the need for additional financing and execution on growth and cost plans. One customer represented 48% of quarterly net sales, highlighting concentration risk. The company continues to promote inFoods IBS and hp+detect while pursuing partnerships and reimbursement pathways.
Biomerica, Inc. presents proxy materials for its annual meeting available online at www.virtualshareholdermeeting.com/BMRA2025 and in person in Irvine, California. The board consists of 5 directors. Insiders — executive officers and directors as a group (six persons) — hold 475,103 shares, representing 16.2% of common stock. The filing discloses director and named executive officer compensation: the chief executive’s reported total in the Summary Compensation Table was
Biomerica, Inc. (BMRA) filed an amendment to its annual report (Form 10-K/A) that discloses corporate governance, executive compensation and equity ownership details. The filing states a 1-for-8 reverse stock split became effective on April 21, 2025, and reports 2,869,900 shares outstanding as of September 26, 2025, producing an implied market value of approximately $6.4 million based on a $3.12 closing price. The document lists the board and executive officers, shows 2024 and 2025 cash and equity compensation for named executives, and details option grants and exercisable options for each named person, with executives and directors as a group beneficially owning 16.2% of the company on a post-split basis.
Biomerica, Inc. (BMRA) reported a net loss of $4,973,000 for fiscal 2025 compared with a $5,978,000 loss in fiscal 2024, showing an improvement in operating results. The company had cash and cash equivalents of approximately $2,399,000 and working capital of about $3,135,000 at May 31, 2025, versus $4,170,000 cash and $5,527,000 working capital a year earlier, indicating reduced liquidity. During the year the company completed ATM sales of 440,687 shares for gross proceeds of ~$2,143,000 and net proceeds of ~$2,015,000. Revenue mix included over-the-counter sales of $1,049,000 and contract manufacturing of $1,070,000, with two distributors accounting for 41% of net sales in 2025. The company’s common stock trades on the Nasdaq Capital Market under the symbol BMRA and a 1-for-8 reverse split became effective April 21, 2025.
FAQ
What is the current stock price of Biomerica (BMRA)?
What is the market cap of Biomerica (BMRA)?
